Published in Cytokine on April 13, 2011
Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Br J Clin Pharmacol (2013) 0.96
After TGN1412: recent developments in cytokine release assays. J Immunotoxicol (2012) 0.92
Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28. MAbs (2014) 0.78
Anti-CD28 Antibody-Initiated Cytokine Storm in Canines. Transplant Direct (2015) 0.76
Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm. J Immunol Methods (2015) 0.75
Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci (2003) 2.87
Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst (2004) 2.41
Biosimilars: what clinicians should know. Blood (2012) 2.28
Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine (2005) 2.27
Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res (2013) 2.26
Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacol Ther (2006) 2.13
"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol (2007) 2.11
Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun (2008) 1.92
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol (2009) 1.90
Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res (2002) 1.86
Biosimilars-why terminology matters. Nat Biotechnol (2011) 1.73
Crucial role of neutrophils in the development of mechanical inflammatory hypernociception. J Leukoc Biol (2008) 1.64
Cardiopulmonary resuscitation feedback improves the quality of chest compression provided by hospital health care professionals. Am J Emerg Med (2010) 1.58
Biomarkers of vitamin B-12 status in NHANES: a roundtable summary. Am J Clin Nutr (2011) 1.43
Biomarkers of folate status in NHANES: a roundtable summary. Am J Clin Nutr (2011) 1.43
The viral mimic, polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. Am J Physiol Regul Integr Comp Physiol (2004) 1.38
In support of the European Union biosimilar framework. Nat Biotechnol (2012) 1.33
Antinociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats. J Pharmacol Exp Ther (2003) 1.30
Circulating interleukin-6 induces fever through a STAT3-linked activation of COX-2 in the brain. Am J Physiol Regul Integr Comp Physiol (2006) 1.20
Tumour necrosis factor-alpha, interleukin-1beta and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Pain (2002) 1.15
Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol (2009) 1.12
Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol (2008) 1.11
Peri-sciatic proinflammatory cytokines, reactive oxygen species, and complement induce mirror-image neuropathic pain in rats. Pain (2004) 1.11
A WHO reference reagent for the Serum Transferrin Receptor (sTfR): international collaborative study to evaluate a recombinant soluble transferrin receptor preparation. Clin Chem Lab Med (2010) 1.11
Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8). J Gen Virol (2008) 1.11
Antihyperalgesic effect of pentoxifylline on experimental inflammatory pain. Br J Pharmacol (2004) 1.09
How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response. Cytokine (2013) 1.08
Interleukin-6 in combination with its soluble IL-6 receptor sensitises rat skin nociceptors to heat, in vivo. Pain (2002) 1.08
Cytokine-induced neutrophil chemoattractant 1 (CINC-1) mediates the sympathetic component of inflammatory mechanical hypersensitivitiy in rats. Eur Cytokine Netw (2003) 1.07
Human CD4+ lymphocytes for antigen quantification: characterization using conventional flow cytometry and mass cytometry. Cytometry A (2012) 1.07
Interleukin-6 and leptin mediate lipopolysaccharide-induced fever and sickness behavior. Physiol Behav (2006) 1.07
Cytokine gene expression in a murine wound healing model. Cytokine (2005) 1.04
Interleukin-6 mediates low-threshold mechanical allodynia induced by intrathecal HIV-1 envelope glycoprotein gp120. Brain Behav Immun (2007) 1.02
Antigen-induced inflammatory mechanical hypernociception in mice is mediated by IL-18. Brain Behav Immun (2006) 1.02
Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain. J Neurosci (2009) 1.01
Genetic modifiers of abnormal organelle biogenesis in a Drosophila model of BLOC-1 deficiency. Hum Mol Genet (2009) 1.00
International validation of novel pyrogen tests based on human monocytoid cells. J Immunol Methods (2005) 0.99
IL-1-driven endogenous IL-10 production protects against the systemic and local acute inflammatory response following intestinal reperfusion injury. J Immunol (2003) 0.97
Role of cytokines in mediating mechanical hypernociception in a model of delayed-type hypersensitivity in mice. Eur J Pain (2008) 0.97
Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Br J Clin Pharmacol (2013) 0.96
Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol Bioeng (2011) 0.96
Nociceptive effect of subcutaneously injected interleukin-12 is mediated by endothelin (ET) acting on ETB receptors in rats. J Pharmacol Exp Ther (2005) 0.95
Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J Immunol Methods (2009) 0.95
Interleukin (IL)-6 and IL-1 beta act synergistically within the brain to induce sickness behavior and fever in rats. Brain Behav Immun (2008) 0.95
From parent to gamete: vertical transmission of Symbiodinium (Dinophyceae) ITS2 sequence assemblages in the reef building coral Montipora capitata. PLoS One (2012) 0.94
Circulating leptin mediates lipopolysaccharide-induced anorexia and fever in rats. J Physiol (2004) 0.94
TNF-alpha and IL-1beta mediate inflammatory hypernociception in mice triggered by B1 but not B2 kinin receptor. Eur J Pharmacol (2007) 0.93
Continuous delivery of human type I interferons (alpha/beta) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model. Blood (2006) 0.92
Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells. Vaccine (2008) 0.92
Attenuated fever in rats during late pregnancy is linked to suppressed interleukin-6 production after localized inflammation with turpentine. J Physiol (2007) 0.92
Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques. PLoS One (2011) 0.92
Comparative cell signalling activity of ultrapure recombinant chaperonin 60 proteins from prokaryotes and eukaryotes. Immunology (2005) 0.91
Developments in clinical cell therapy. Cytotherapy (2010) 0.91
Differences in the relative involvement of peripherally released interleukin (IL)-6, brain IL-1β and prostanoids in mediating lipopolysaccharide-induced fever and sickness behavior. Psychoneuroendocrinology (2010) 0.91
Differential regulation of type I and type II interleukin-1 receptors in focal brain inflammation. Eur J Neurosci (2005) 0.90
The critical role of leukotriene B4 in antigen-induced mechanical hyperalgesia in immunised rats. Br J Pharmacol (2003) 0.90
Attitudes toward obsessive-compulsive disorders--an experimental investigation. Soc Psychiatry Psychiatr Epidemiol (2003) 0.89
Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration. Pharm Res (2010) 0.89
In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop. Cytokine (2010) 0.89
Selective contribution of interleukin-6 and leptin to brain inflammatory signals induced by systemic LPS injection in mice. J Comp Neurol (2008) 0.89
Effect of a BLT receptor antagonist in a model of severe ischemia and reperfusion injury in the rat. Eur J Pharmacol (2002) 0.88
Using a medical simulation center as an electronic health record usability laboratory. J Am Med Inform Assoc (2013) 0.87
Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol Lett (2002) 0.87
European perspective on biosimilars. Bioanalysis (2013) 0.87
Safety pharmacology--current and emerging concepts. Toxicol Appl Pharmacol (2013) 0.86
Haematopoietic growth factors and their therapeutic use. Thromb Haemost (2008) 0.86
How do we assure the quality of biological medicines? Drug Discov Today (2008) 0.86
An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products. J Interferon Cytokine Res (2010) 0.86
Counter-regulation of interleukin-1alpha (IL-1alpha) and IL-1 receptor antagonist in murine keratinocytes. J Invest Dermatol (2005) 0.85
WHO/KFDA joint workshop on implementing WHO guidelines on evaluating similar biotherapeutic products, Seoul, Republic of Korea 24-26 August, 2010. Biologicals (2011) 0.85
Immune-to-brain signaling and central prostaglandin E2 synthesis in fasted rats with altered lipopolysaccharide-induced fever. Am J Physiol Regul Integr Comp Physiol (2008) 0.85
Unwanted immunogenicity: lessons learned and future challenges. Bioanalysis (2010) 0.84
Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-β1 under the control of dietary xylan 1. Inflamm Bowel Dis (2010) 0.83